IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer-Reference-Cited by-同舟云学术

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer

Published:2019-10-06 Issue:8 Volume:146 Page:2348-2359
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Kruger Dinja T.¹²^ORCID,Alexi Xanthippi³,Opdam Mark²,Schuurman Karianne³,Voorwerk Leonie²⁴,Sanders Joyce⁵,Noort Vincent⁶,Boven Epie¹,Zwart Wilbert³⁷^ORCID,Linn Sabine C.²⁸⁹^ORCID

Affiliation:

1. Department of Medical OncologyAmsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam Amsterdam The Netherlands

2. Division of Molecular PathologyThe Netherlands Cancer Institute Amsterdam The Netherlands

3. Division of OncogenomicsOncode Institute, The Netherlands Cancer Institute Amsterdam The Netherlands

4. Division of Molecular Oncology & ImmunologyThe Netherlands Cancer Institute Amsterdam The Netherlands

5. Department of PathologyThe Netherlands Cancer Institute Amsterdam The Netherlands

6. Division of BiometricsThe Netherlands Cancer Institute Amsterdam The Netherlands

7. Department of Biomedical EngineeringEindhoven University of Technology Eindhoven The Netherlands

8. Department of Medical OncologyThe National Cancer Institute Amsterdam The Netherlands

9. Department of PathologyUniversity Medical Center Utrecht Utrecht The Netherlands

Funder

Stichting A Sister's Hope

Top Institute Pharma

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32668

Reference47 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

2. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

3. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

4. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

5. Endocrine treatment in breast cancer: Cure, resistance and beyond

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells;MedComm;2023-08-24

2. A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer;BMC Medical Research Methodology;2023-06-29

3. Pan‐cancer analysis of oncogenic role of insulin‐like growth factor‐binding proteins and validation in ovarian cancer;Cancer Medicine;2023-05-18

4. Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer;PLOS ONE;2023-03-15

5. Obesity and endocrine-related cancer: The important role of IGF-1;Frontiers in Endocrinology;2023-01-23